CTOs on the Move

Imperative Care

www.imperativecare.com

 
Were reimagining how technology can solve #stroke`s unmet needs, enabling providers with the ability to raise the standard of care for patients.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Jim Lay
Senior Director Information Technology Profile

Funding

Imperative Care raised $85M on 12/10/2019

Similar Companies

Bactolac Pharmaceutical Inc

We are completely committed to the success of every one of our client-partners and dedicate ourselves to quality and efficiency. We provide custom formulation and quality manufacturing for your existing formulas and welcome the opportunity to provide

Regulatory Compliance Associates Inc

Regulatory Compliance Associates Inc is a Kenosha, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EAG Life Sciences

EAG Life Sciences is a Maryland Heights, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CutisPharma

CutisPharma is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Radius Health

Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius` lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius` Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius` RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. Radius was founded in 2003 and has locations in Waltham and Cambridge, Massachusetts, Parsippany, New Jersey, and Wayne, Pennsylvania.